MedTrace Logo

A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

NCT05303285 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in Chinese adults participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).

Conditions

  • Ankylosing Spondylitis (AS)

Interventions

DRUG

Secukinumab 300mg s.c.

Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks

DRUG

Secukinumab 150mg s.c.

Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks

Sponsors & Collaborators

  • Wuhan Central Hospital

    collaborator OTHER

  • Wuhan Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Novartis

    collaborator INDUSTRY

  • Johns Hopkins Bloomberg School of Public Health

    collaborator OTHER

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • AIHUA DU, M.D · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-14
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05303285 on ClinicalTrials.gov